REVIEW PAPER
Proton pump inhibitors – their possible influence on the development of small intestine bacterial overgrowth in children
1
Department of Pediatrics, Allergology and Gastroenterology, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland
2
Department of Pediatrics Endoscopy and Gastrointestinal Function Testing, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland
Submission date: 2022-10-22
Final revision date: 2022-12-21
Acceptance date: 2022-12-29
Publication date: 2023-06-19
Corresponding author
Zuzanna Wasielewska
Zuzanna Wasielewska, MD, Department of Pediatrics, Allergology and Gastroenterology, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland
Zuzanna Wasielewska, MD, Department of Pediatrics, Allergology and Gastroenterology, Collegium Medicum Nicolaus Copernicus University, Bydgoszcz, Poland
Pediatr Pol 2023;98(2):154-160
KEYWORDS
childrenproton pump inhibitorssmall intestinal bacterial overgrowthgut microbiomesmall intestine bacterial overgrowth
TOPICS
ABSTRACT
Proton pump inhibitors (PPIs) are safe drugs that have been commonly used for many years by both general practitioners and specialists. They are widely used in the paediatric population, mainly in the treatment of gastroesophageal reflux disease, but also for oesophagitis, gastritis and/or duodenitis. Proton pump inhibitors use increases the pH of the stomach, which disrupts the physiological defensive barrier and may lead to the development of an abnormal microbiome in the further parts of the digestive tract, resulting in small intestinal bacterial overgrowth (SIBO) and symptoms such as diarrhoea, production of gas, nonspecific abdominal pain, flatulence, lack of growth or weight loss, protein or energy malnutrition, and vitamin A, D, K and B12 deficiency. The study analyses the influence of combining PPIs with probiotics or prokinetics on the chance of SIBO developing in children. There are currently no diagnostic standards or therapeutic guidelines for children diagnosed with SIBO.
REFERENCES (48)
1.
Houben E, Johansson S, Nagy P, et al. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists. Curr Med Res Opin 2018; 34: 577-583.
2.
Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150: 262-267.
3.
Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol 2015; 80: 200-208.
4.
Poddar U. Gastroesophageal reflux disease (GERD) in children. Paediatr Int Child Health 2019; 39: 7-12.
5.
De Bruyne P, Ito S. Toxicity of long-term use of proton pump inhibitors in children. Arch Dis Child 2018; 103: 78-82.
6.
Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66: 516-554.
7.
Avelar Rodriguez D, Ryan PM, Toro Monjaraz EM, et al. Small intestinal bacterial overgrowth in children: a state-of-the-art review. Front Pediatr 2019; 7: 363.
8.
Li J, Zhao J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28: 419-427.
9.
Zhao J, Li J, Hamer-Maansson JE, et al. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28: 1868-1876.
10.
Collins BS, Lin HC. Chronic abdominal pain in children is associated with high prevalence of abnormal microbial fermentation. Dig Dis Sci 2010; 55: 124-130.
11.
Sieczkowska A, Landowski P, Kamińska B, et al. Small bowel bacterial overgrowth in children. J Pediatr Gastroenterol Nutr 2016; 62: 196-207.
12.
Grace E, Shaw C, Whelan K, et al. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 2013; 38: 674-688.
13.
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16: 2978-2990.
14.
Sachdev AH, Pimentel M. Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. Ther Adv Chronic Dis 2013; 4: 223-231.
15.
Grzybowska-Chlebowczyk U. Zespół przerostu bakteryjnego jelita cienkiego – kiedy diagnozować, kiedy leczyć? Standard Med Ped 2018; 18: 441-447.
16.
Ghoshal UC, Shukla R, Ghoshal U. Small intestinal bacterial overgrowth and irritable bowel syndrome: a bridge between functional organic dichotomy. Gut Liver 2017; 11: 196-208.
17.
Harmsen HJ, de Goffau MC. The human gut microbiota. Adv Exp Med Biol 2016; 902: 95-108.
18.
Siniewicz-Luzeńczyk K, Bik-Gawin A, Zeman K, et al. Small intestinal bacterial overgrowth syndrome in children. Prz Gastroenterol 2015; 10: 28-32.
19.
Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol 2016; 10: 215-227.
20.
Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: an evidence-based approach. Curr Gastroenterol Rep 2016; 18: 8.
21.
Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil 2015; 27: 481-489.
22.
Nowak M, Gulbicka P, Grzymisławski M. Wodorowe testy oddechowe jako narzędzie w diagnostyce schorzeń gastroenterologicznych. Forum Zab Metab 2015; 6: 124-135.
23.
Rezaie A, Buresi M, Lembo A, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: the North American consensus. Am J Gastroenterol 2017; 112: 775-784.
24.
Ghoshal UC. How to interpret hydrogen breath tests. J Neurogastroenterol Motil 2011; 17: 312-317.
25.
Di Stefano M, Mengoli C, Bergonzi M i wsp. Hydrogen breath test and intestinal gas production. Eur Rev Med Pharmacol Sci 2013; 17: 36-38. .
26.
Losurdo G, Leandro G, Ierardi E, et al. Breath tests for the non-invasive diagnosis of small intestinal bacterial overgrowth: a systematic review with meta-analysis. J Neurogastroenterol Motil 2020; 26: 16-28.
27.
Dos Reis JC, de Morais MB, Oliva CA, et al. Breath hydrogen test in the diagnosis of environmental enteropathy in children living in an urban slum. Dig Dis Sci 2007; 52: 1253-1258.
28.
Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr 2009; 155: 416-420.
29.
Belei O, Olariu L, Dobrescu A, et al. The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents. J Pediatr Endocrinol Metab 2017; 30: 1161-1168.
30.
Belei O, Olariu L, Dobrescu A, et al. Is It useful to administer probiotics together with proton pump inhibitors in children with gastroesophageal reflux?. J Neurogastroenterol Motil 2018; 24: 51-57.
31.
De Boissieu D, Chaussain M, Badoual J, et al. Small-bowel bacterial overgrowth in children with chronic diarrhea, abdominal pain, or both. J Pediatr 1996; 128: 203-207.
32.
Pignata C, Budillon G, Monaco G, et al. Jejunal bacterial overgrowth and intestinal permeability in children with immunodeficiency syndromes. Gut 1990; 31: 879-882.
33.
Lisowska A, Wójtowicz J, Walkowiak J. Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. Acta Biochim Pol 2009; 56: 631-634.
34.
Lewindon PJ, Robb TA, Moore DJ, et al. Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998; 34: 79-82.
35.
Levy EI, Hoang DM, Vandenplas Y. The effects of proton pump inhibitors on the microbiome in young children. Acta Paediatr 2020; 109: 1531-1538.
36.
Sieczkowska A, Landowski P, Zagozdzon P, et al. Small bowel bacterial overgrowth associated with persistence of abdominal symptoms in children treated with a proton pump inhibitor. J Pediatr 2015; 166: 1310-1312.
37.
Cares K, Al-Ansari N, Macha S, et al. Short article: risk of small intestinal bacterial overgrowth with chronic use of proton pump inhibitors in children. Eur J Gastroenterol Hepatol 2017; 29: 396-399.
38.
Hegar B, Hutapea EI, Advani N, et al. A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole. J Pediatr (Rio J) 2013; 89: 381-387.
39.
Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest 2011; 41: 380-386.
40.
Su T, Lai S, Lee A, et al. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol 2018; 53: 27-36.
41.
Sieczkowska A, Landowski P, Gibas A, et al. Long-term proton pump inhibitor therapy leads to small bowel bacterial overgrowth as determined by breath hydrogen and methane excretion. J Breath Res 2018; 12: 036006.
42.
Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011; 33: 1059-1067.
43.
Ratuapli SK, Ellington TG, O’Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. Am J Gastroenterol 2012; 107: 730-735.
44.
Revaiah PC, Kochhar R, Rana SV, et al. Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. JGH Open 2018; 2: 47-53.
45.
Shah SC, Day LW, Somsouk M, et al. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38: 925-934.
46.
Ghoshal UC, Sachdeva S, Ghoshal U, et al. Asian-Pacific consensus on small intestinal bacterial overgrowth in gastrointestinal disorders: an initiative of the Indian Neurogastroenterology and Motility Association. Indian J Gastroenterol 2022; 41: 483-507.
47.
Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology 2020; 159: 1526-1532.
48.
Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17: 1314-1320.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
